A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
The user has been using finasteride for almost a year, starting at age 18, and added tretinoin and 5% topical minoxidil 1-2 months ago. They are concerned about hair receding again despite the treatments.
The user shared progress pictures showing improved hair growth at the temples after 2.5 months using oral finasteride/dutasteride, ketoconazole shampoo, minoxidil, tretinoin, and dermarolling. The user reported no side effects from the medications and noted inconsistent microneedling.
The conversation is about using ketoconazole shampoo for hair loss, specifically discussing concerns about benzyl alcohol in popular brands and seeking experiences with the "tiniazol" brand. The user is considering adding this shampoo to their routine.
The conversation discusses choosing between titanium fixed needles and a pen with disposable needles for hair loss treatment at a 1.5mm depth. The preference is for disposable needles for better sanitization.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
A user discusses a hair loss treatment combining minoxidil and tretinoin, noting it may enhance absorption. Some users express interest and share positive experiences, while others question its effectiveness without medical evidence.
The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.
A 24-year-old shares progress on hair regrowth after 3 months using 2.5mg oral minoxidil, 0.5mg dutasteride, and scalp injections of dutasteride, minoxidil, and vitamins every two weeks. They are uncertain if the improvement is due to actual regrowth or just longer hair.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.
The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.
User "logart89" claims DUT 3 times a week is better than daily FIN for hair loss. Their routine includes DUT, topical DUT, stemoxydine and alfatradiol mix, 5% minoxidil with tretinoin, and weekly derma stamping.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
A 35-year-old shared a 2-month update on their hair transplant of 3153 grafts, noting redness, itching, and some pimples, while using finasteride for over 12 years to maintain hair. Users discussed the effectiveness and timing of starting finasteride, with some suggesting consulting a doctor for young individuals considering the treatment.
A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.
Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.